IBIO - iBio Inc Debt to Book Capitalization Ratio

Graphic logo of iBio Inc (IBIO)

iBio, Inc. (IBIO) faces challenges regarding its strategic pivot and rapid cash burn, as evidenced by the company's total debt-to-equity ratio on this GURU.Markets service chart, where the 0.03 mark characterizes this parameter. Proprietary protein synthesis methods create significant barriers to entry. The business is currently implementing AI to accelerate the discovery of therapeutic antibodies in immuno-oncology.

IBIO (iBio Corporation) Debt to Book Value history from 07/04/2022 to 10/27/2026
Core merchandise of iBio Inc

A conservative approach requires strict control of the debt load relative to the value of net assets. This metric compares total liabilities with book capitalization, revealing the extent of the business's dependence on borrowed funds. By analyzing the capital structure trend of debt to book capitalization, an investor assesses the company's insolvency risk. For iBio, Inc. (IBIO), this indicator is critical due to the lack of merger prospects and dependence on future licenses. High volatility of this metric underscores the fragility of the biotech startup's financial stability.

Who iBio, Inc. competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Debts to Book Capitalization IMNM (Immunome Corp)|GOSS - Debts to Net Assets|KalVista Pharmaceuticals (KALV) - Debts to Book Capitalization|septerna.com (SEPN) - Debt to Book Capitalization Ratio|PVLA: Debts to Book Capitalization|Debts to Net Assets SVRA|Rigel Pharmaceuticals Inc - Debt to Book Capitalization Ratio|Debts to Book Value AnaptysBio Inc. ANAB|Debt to Book Value Astria Therapeutics|Debt to Net Assets Ratio engene.com ENGN|Debts to Book Capitalization RAPT (RAPT Therapeutics, Inc.)|JBIO: Debts to Net Assets|Debt to Book Capitalization Ratio Aclaris|Kyverna Therapeutics, Inc (KYTX) - Debt to Book Value Ratio|Debts to Book Capitalization TLSA|Debt to Book Value cabalettabio.com (CABA)|VTYX (Ventyx Biosciences, Inc.) - Debt to Book Value|Debts to Net Assets Theratechnologies, Inc. (THTX)|Debts to Book Capitalization AVTX|Debts to Net Assets Eledon Pharmaceuticals, Inc ELDN|AGEN - Debts to Book Capitalization|CLYM - Debt to Book Capitalization Ratio|Zura Bio Limited - Debts to Book Capitalization|ATYR (aTyr Pharma Inc) - Debts to Net Assets|Debt to Book Capitalization Ratio ADAG (Adagene Inc)|Debts to Book Value IMA|STTK - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio equilliumbio.com (EQ)|Debts to Book Capitalization Connect Biopharma Holdings Limited|Debt to Net Assets Ratio Immunic Therapeutics IMUX|Atara Biotherapeutics Inc - Debts to Book Capitalization|IFRX: Debts to Book Capitalization|Debt to Book Capitalization Ratio X4 Pharmaceuticals XFOR|ACET (Adicet Bio, Inc.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio CELU|Debt to Book Value INmune Bio Inc|Debts to Book Capitalization BRNS|Debts to Book Capitalization Kezar Life Sciences Inc KZR|Debt to Book Value SAB Biotherapeutics|Debt to Net Assets Ratio akaritx.com AKTX|Debts to Book Capitalization ENLV (Enlivex Therapeutics, Ltd.)|QTTB: Debts to Net Assets|GOVX (GeoVax Labs Inc) - Debt to Book Capitalization Ratio|EDSA (Edesa Biotech Corp) - Debt to Book Value|Debt to Book Capitalization Ratio CARM|Debt to Book Value xtlbio.com (XTLB)|Debt to Book Value BOLT|Debts to Book Capitalization HCWB (hcwbiologics.com)|APVO - Debt to Book Capitalization Ratio|Debt to Book Value Ratio AIM ImmunoTech, Inc. AIM|ADTX (Aditxt Corp) - Debts to Book Capitalization|GRI - Debts to Book Value|XORTX Therapeutics - Debts to Book Capitalization|Vyome Holdings Inc. (HIND) - Debts to Net Assets|Debts to Book Capitalization Revelation Bio|Debt to Book Capitalization Ratio Indaptus Corp|SCNI (Scinai Immunotherapeutics) - Debts to Book Capitalization|Debts to Net Assets CALI (calcimedica.com)|AFMD: Debt to Book Capitalization Ratio|ALLK - Debts to Book Value|Debt to Book Value HOOKIPA (HOOK)|IGMS - Debt to Net Assets Ratio|iTeos Therapeutics - Debts to Book Capitalization|OCEA (oceanbiomedical.com) - Debts to Net Assets|Debt to Book Capitalization Ratio TC BioPharm (TCBP)|Debt to Book Value Ratio Third Harmonic Bio Inc.